Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome

Tissue Antigens

Volumn 71, Issue 1, 2008, Pages 16-26

  Nowak, J ^a   Kalinka Warzocha, E ^b   Juszczynski P ^c   Mika Witkowska, R ^a   Zajko, M ^a   Graczyk Pol, E ^a   Coiffier, B ^d   Salles, G ^d   Warzocha, K ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b Regional Oncological Centre   (Poland)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Association; Killer immunoglobulin like receptor ligands; Major histocompatibility complex haplotypes; Non Hodgkin's lymphoma; Prognosis

Indexed keywords

HLA A ANTIGEN; LYMPHOTOXIN; TUMOR NECROSIS FACTOR;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PREDICTION AND FORECASTING; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-D ANTIGENS; HLA-DR ANTIGENS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 36949024684     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2007.00954.x     Document Type: Article

References (35)

1. Warzocha K, Ribeiro P, Bienvenu J et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998 : 91 : 3574 81.
2. Silvestris N, Crucitta E, Lorusso V, Gamucci T, De Lena M. AIDS-related non-Hodgkin's lymphoma: clinico-pathological characteristics and therapeutic strategies. Int J Oncol 2002 : 20 : 611 5.
3. Kuppers R, Klein U, Hansmann M-L, Rajewsky K. Cellular origin of human B-cell lymphomas. New Engl J Med 1999 : 341 : 1520 9.
4. Lamberth K, Claesson MH. Ligation of major histocompatibility complex class I antigens (MHC-I) prevents apoptosis induced by Fas or SAPK/JNK activation in T-lymphoma cells. Tissue Antigens 2001 : 58 : 171 80.
5. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002 : 99 : 609 17.
6. Berger CL, Edelson R. The life cycle of cutaneous T cell lymphoma reveals opportunities for targeted drug therapy. Curr Cancer Drug Targets 2004 : 4 : 609 19.
7. Warzocha K, Ribeiro P, Renard N et al. Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas. Cancer Immunol Immun 2000 : 49 : 469 75.
8. Juszczynski P, Kalinka E, Bienvenu J et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002 : 100 : 3037 40.
9. Seidemann K, Zimmermann M, Book M et al. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Munster trial NHL-BFM 95. J Clin Oncol 2005 : 23 : 8414 21.
10. Rothman N, Skibola CF, Wang SS et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006 : 7 : 27 38.
11. Cohen BA, Mitra RD, Hughes JD, Church GM. A computational analysis of whole-genome expression data reveals chromosomal domains of gene expression. Nat Genet 2000 : 26 : 183 6.
12. Candore G, Lio D, Colonna Romano G, Caruso C. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 2002 : 1 : 29 35.
13. Flores-Villanueva PO, Hendel H, Caillat-Zucman S et al. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J Immunol 2003 : 170 : 1925 9.
14. Crawford DC, Bhangale T, Li N et al. Evidence for substantial fine-scale variation in recombination rates across the human genome. Nat Genet 2004 : 36 : 700 6.
15. Lewontin RC. The interaction of selection and linkage. I. General considerations; Heterotic models. Genetics 1964 : 49 : 49 67.
16. Blomhoff A, Olsson M, Johansson S et al. Linkage disequilibrium and haplotype blocks in the MHC vary in an HLA haplotype specific manner assessed mainly by DRB1*03 and DRB1*04 haplotypes. Genes Immun 2006 : 7 : 130 40.
17. Nowak J, Kalinka-Warzocha E, Juszczynski P et al. Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. Gene Chromosome Canc 2007 : 46 : 500 7.
18. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989 : 7 : 1018 26.
19. Tartaglia AT, Pennica D, Goedddel DV. Ligand passing: the 75kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993 : 268 : 18542 8.
20. Olsson I, Gatanaga T, Gullberg U, Lantz M, Granger GA. Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw 1993 : 4 : 169 80.
21. Salles G, Bienvenu J, Bastion Y et al. Elevated circulating levels of TNFα and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol 1996 : 93 : 352 9.
22. Warzocha K, Bienvenu J, Ribeiro P et al. Plasma levels of tumor necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 1998 : 77 : 2357 62.
23. Carrington M, Norman PJ. The KIR Gene Cluster. National Library of Medicine (U.S.). Bethesda: NCBI, 2003.
24. Raymond M, Rousset F. GENEPOP version 1.2: population genetics software for exact tests and ecumenicism. J Heredity 1995 : 86 : 248 9.
25. Stephens M, Smith N, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Human Genet 2001 : 68 : 978 89.
26. Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New Engl J Med 1993 : 329 : 987 94.
27. Herr M, Dudbridge F, Zavattari P et al. Evaluation of fine mapping strategies for a multifactorial disease locus: systematic linkage and association analysis of IDDM1 in the HLA region on chromosome 6p21. Hum Mol Genet 2000 : 9 : 1291 301.
28. Boodhoo A, Wong AM-I, Williamson D et al. A promoter polymorphism in the central MHC gene, IKBL, influences the binding of transcription factors USF1 and E47 on disease-associated haplotypes. Gene Expression 2004 : 12 : 1 11.
29. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993 : 177 : 557 60.
30. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004 : 103 : 3065 72.
31. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999 : 285 : 727 9.
32. Fischer G, Arguello JR, Perez-Rodriguez M et al. Sequence-specific oligonucleotide probing for MICB alleles reveals associations with MICA and HLA-B. Immunogenetics 2000 : 51 : 591 9.
33. Braud VM, Allan DS, O'Callaghan CA et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998 : 391 : 795 9.
34. Hoban PR, Lear JT, Strange RC. Skin cancer: basal cell carcinoma: genetic homogeneity in a tumour type displaying phenotypic diversity. Eur J Hum Genet 2006 : 14 : 977 8.
35. Shichi D, Kikkawa EF, Ota M et al. The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. Tissue Antigens 2005 : 66 : 200 8.